Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy

Caribou Biosciences, Inc. announced that the US FDA has granted CB-010 RMAT designation for relapsed or refractory large B cell lymphoma and Fast Track designation for relapsed or refractory B cell non-Hodgkin lymphoma.